B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
OCS
OculisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
PREDICT-1 succeeds, PIONEER-1 recruitment progresses, and the proposed Accure transaction improves Privosegtor economics. June 30 cash and short-term investments of $282.3 million support management's stated runway into the second half of 2029 [#PR-EARNINGS-2026-08-06].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -9.8.
What can break
A negative or delayed PREDICT-1 readout could materially impair the remaining pipeline thesis.
Momentum
4
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $4.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $36.82
Why
Momentum4 · Δ7d -0.1
Value41 · Δ7d -0.1
Sentiment61 · Δ7d -9.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -9.8.
Contradictions & invalidation
- • A negative or delayed PREDICT-1 readout could materially impair the remaining pipeline thesis.
- • Although management projects runway into the second half of 2029, the June 30 cash balance partly reflected at-the-market share sales, creating dilution risk [#PR-EARNINGS-2026-08-06].
- • Both DIAMOND Phase 3 trials missed their primary vision endpoint, and Oculis does not plan a DME filing for OCS-01.
Catalyst clock
2026-12-31
Licaminlimab PREDICT-1 topline results
Lead driver: Sentiment · See AI snapshot
Momentum
4
8% active weight
Current posture
7d trendSoftening
Δ7d
-0.1
Δ21d
-0.5
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
61
45% active weight
Current posture
7d trendSoftening
Δ7d
-9.8
Δ21d
+4.7
Why this grade
Composite grade D. Momentum 4.3 / Value 40.6 / Sentiment 60.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$487.68M
Beta
0.14
Shares Out
61.73M
P/E (TTM) · Derived
-3.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.47
Rev YoY
-
EPS YoY
-64.9%
Gross Margin
-
Op Margin
-
Net Debt
-$265.95M
Current Ratio
8.35
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data